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Abstract
Background: Genome-wide association studies have identified over 160 loci that are associated with coronary artery
disease. As with other complex human diseases, risk in coronary disease loci is determined primarily by altered expression
of the causal gene, due to variation in binding of transcription factors and chromatin-modifying proteins that
directly regulate the transcriptional apparatus. We have previously identified a coronary disease network
downstream of the disease-associated transcription factor TCF21, and in work reported here extends these
studies to investigate the mechanisms by which it interacts with the AP-1 transcription complex to regulate
local epigenetic effects in these downstream coronary disease loci.
Methods: Genomic studies, including chromatin immunoprecipitation sequencing, RNA sequencing, and protein-
protein interaction studies, were performed in human coronary artery smooth muscle cells.
Results: We show here that TCF21 and JUN regulate expression of two presumptive causal coronary disease genes,
SMAD3 and CDKN2B-AS1, in part by interactions with histone deacetylases and acetyltransferases. Genome-wide TCF21
and JUN binding is jointly localized and particularly enriched in coronary disease loci where they broadly modulate
H3K27Ac and chromatin state changes linked to disease-related processes in vascular cells. Heterozygosity at coronary
disease causal variation, or genome editing of these variants, is associated with decreased binding of both JUN and
TCF21 and loss of expression in cis, supporting a transcriptional mechanism for disease risk.
Conclusions: These data show that the known chromatin remodeling and pioneer functions of AP-1 are a pervasive
aspect of epigenetic control of transcription, and thus, the risk in coronary disease-associated loci, and that interaction
of AP-1 with TCF21 to control epigenetic features, contributes to the genetic risk in loci where they co-localize.
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Background
Collaborative efforts from multiple large genome-wide
association studies (GWAS) in the past decade have
identified 161 independent genomic loci significantly
associated with CAD in humans [1–4]. While a small
subset of coronary artery disease (CAD) variants alter
specific protein composition, the majority of the identi-
fied lead SNPs (single nucleotide polymorphisms) are
located in non-coding enhancer regions, suggesting that
variation in cellular transcriptional response rather than
protein function underlies the majority of heritable
disease risk [5]. Although identified genetic loci offer
great promise in advancing our understanding of CAD
pathophysiology, these transcriptional regulatory regions
are poorly annotated, and thus, the mechanisms by
which the causal variants affect causal gene expression
are poorly understood. Identifying the transcriptional
mechanisms shared among multiple CAD risk loci will
not only provide new insights into the pathophysiology of
CAD, but will also allow us to identify core mechanisms
for intervention to modify disease risk.
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TCF21 is a basic helix-loop transcription factor critical
in cardiovascular development and disease [2–4, 6–14].
In the context of atherosclerosis, an important feature of
TCF21 biology is the fact that it regulates fundamental
cellular differentiation events in the developing epicar-
dium, serving as a determining factor for the divergence
between coronary vascular smooth muscle cell (SMC)
and cardiac fibroblast lineages [15, 16]. Embryonic loss
of Tcf21 has been linked to premature differentiation of
SMC from the pericardium, resulting in decreased
migration into the myocardium [16]. TCF21 has been
extensively associated with CAD risk, having been asso-
ciated with disease in multiple racial ethnic groups [14,
17, 18]. Vascular smooth muscle cell expression quanti-
tative trait locus (eQTL) studies [19], as well mechanistic
follow-up studies, have identified TCF21 as the causal
gene in the CAD-associated locus at 6q23.2 [20] and
suggested that expression of this gene is protective
toward CAD risk [21]. Further, TCF21 has been shown
to be expressed in cells that migrate into the developing
plaque and contribute to the protective fibrous cap [22].
TCF21 downstream target regions are enriched for
known CAD risk loci, suggesting that TCF21 plays a
central role in regulating risk in other loci to effect the
biology of atherosclerotic plaques [23].
The activated protein-1 (AP-1) family of proteins
includes a number of bZip transcription factors that
bind primarily as heterodimers to a well-characterized
canonical DNA sequence. Expression of these early
response genes (e.g., FOS, FOSB, JUN, JUND) is initiated
in all cell types when growth factors activate their cog-
nate receptor tyrosine kinases, inducing the Ras/MAPK
intracellular kinase cascade, promoting a variety of cell
state changes [24–26]. These AP-1 site-binding proteins
have been shown to play a central role in specific linea-
ge-restricted enhancer selection and function [27, 28].
FOS/JUN factors select enhancers with cell type-specific
transcription factors (TFs) by collaboratively binding to
histone bound enhancers and recruiting the BAF chroma-
tin remodeling complex to establish accessible chromatin
[29]. At a more general level, AP-1 factors have been
shown to disrupt the nucleosomal structure and regulate
chromatin accessibility in various cell types [29–31]. In the
context of complex diseases, variation in AP-1 binding
sites has been shown to mediate genetic risk [20, 32–35].
An AP-1 site in an intron of the SMAD3 gene has been
implicated in the association of this gene with CAD, as
well as an autoimmune disease [20, 33–35]. Important for
this discussion, AP-1 binding sites in two different
CAD-associated alleles that regulate expression of TCF21
have been shown to alter risk in Caucasian and East Asian
populations [14, 17, 20].
In studies reported here, we have investigated the
interaction of transcription factors TCF21 and AP-1 at
loci identified by GWAS to regulate risk for the CAD
phenotype, focusing on 15q22.33 and 9p21.3. Studies
employing eQTL mapping, allele-specific expression,
co-localization of eQTL and GWAS, in vitro experiments,
cell culture, and animal models have identified SMAD3
[19, 33, 36, 37] and CDKN2B-AS1 (CDKN2BAS) [38–42]
as putative causal genes in these loci. We show that
TCF21 and AP-1 regulate expression of these genes by
regulating chromatin accessibility through interactions
with histone acetyltransferases and histone deacetylases
and also through protein-protein interactions. We
subsequently generalize our finding on these two loci
genome-wide and demonstrate that interaction between
AP1 and TCF21 controls epigenetic features in regions
where they co-localize. These regions are enriched for
CAD genetic risk loci, suggesting a critical role for this
interaction in modifying risk for CAD.
Methods
Primary cell culture and reagents
Primary human coronary artery smooth muscle cells
(HCASMCs) derived from normal human donor hearts
were purchased from three different manufacturers
Lonza, PromoCell, and Cell Applications (all tested
negative for mycoplasma contamination) at passage 2
and were maintained in growth-supplemented smooth
muscle basal media (Lonza # CC-3182) according to the
manufacturer’s instructions. All experiments were per-
formed on HCASMCs between passages 4 and 7. Anti-
bodies used for ChIPseq and ChIP-quantitative PCR
(qPCR) were all pre-validated according to ChIPseq
guidelines and ENCODE best practices. Purified mouse
monoclonal antibodies against human JUN (sc-74543)
and p300 (sc-48343) were purchased from Santa Cruz.
Purified rabbit polyclonal antibody against H3K27ac
(ab4729), HDAC1 (ab7028), and HDAC2 (ab7029) were
purchased from Abcam. Purified rabbit polyclonal anti-
body against human TCF21 (HPA013189) was purchased
from Sigma.
Knockdown and overexpression
JUN (s7659) and p300 (s534247) silencer select siRNAs
were purchased from Thermo Fisher Scientific. TCF21
(SR321985) Trilencer-27 siRNAs were purchased from
OriGene. siRNA transfection was performed using Lipo-
fectamine RNAiMAX (Life Technologies). For each well
treated with the siRNAs or scrambled control (Life Tech-
nologies, #4390843), the final concentration was 20 nM.
HCASMCs were seeded in 6-well plates and grown to
50% confluence before siRNA transfection. HCASMCs
were transfected with the siRNA or scrambled control for
6–8 h and subsequently collected and processed for RNA
isolation after 48 h of transfection using the RNeasy mini
kit (Qiagen 74106).
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For lentivirus transduction study, control (titer 5.68 × 107),
TCF21 cDNA (titer 3.84 × 106), and shRNA (titer 2.59 × 107)
virus were used as described before [22]. JUN shRNA (titer
8.4 × 108) virus was purchased from OriGene (TL320397).
HCASMCs were transduced with the virus at a density
of 5 × 105 cells per T75-flask. Cells were changed to
medium with supplements 12 h after transduction and
cultured for an additional 48 h. The transduction effi-
ciency was assessed by quantifying the percentage of
GFP-positive cells. Transduction efficiencies were more
than 90%.
RNA isolation and qRT-PCR
RNA for all samples was extracted using the RNeasy mini
kit (Qiagen 74106). HCASMC RNA (500 ng) was reverse
transcribed using the High-Capacity RNA-to-cDNA
Synthesis kit (Applied Biosystems 4387406). Quantitative
PCR of the cDNA samples was performed on a ViiA7
Real-Time PCR system, and gene expression levels were
measured using SYBR green assays (Applied Biosystems
4368706) using custom-designed primers and normalized
to ACTB levels. Comparison between two groups was
performed using the Student’s t test, and comparisons
between the three groups were performed using ANOVA.
qPCR primers were designed as follows: SMAD3,
Fwd: CCATCTCCTACTACGAGCTGAA, Rev: CACT
GCTGCATTCCTGTTGAC, Amplicon: 149 bp; CDKN2BAS,
Fwd: CTATCCGCCAATCAGGAGGC, Rev: GCGTGCAGC
GGTTTAGTTTA, Amplicon: 103 bp; CDKN2B, Fwd:
GGGACTAGTGGAGAAGGTGC, Rev: CATCATCAT
GACCTGGATCGC, Amplicon: 97 bp; JUN, Fwd: TCCA
AGTGCCGAAAAAGGAAG, Rev: CAGCACAATGAAG
ATCAAGA, Amplicon: 78 bp; TCF21, Fwd: TCCT
GGCTAACGACAAATACGA, Rev: TTTCCCGGCCACCA
TAAAGG, Amplicon: 77 bp; EP300, Fwd: GCTTCAGAC
AAGTCTTGGCAT, Rev: ACTACCAGATCGCAGCAAT
TC, Amplicon: 79 bp.
ChIP assay
Briefly, approximately 4e6 HCASMC cells were fixed with
1% formaldehyde and quenched by glycine. The cells were
washed three times with PBS and then harvested in ChIP
lysis buffer (50mM Tris-HCl, pH 8, 5mM EDTA, 0.5%
SDS). Crosslinked chromatin was sheared for 3 × 1 min by
sonication (Branson SFX250 Sonifier) before extensive
centrifugation. Four volumes of ChIP dilution buffer
(20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA,
1% Triton X-100) was added to the supernatant. The
resulting lysate was then incubated with Dynabeads™
Protein G (Thermo Scientific, 10009D) and antibodies
at 4 °C overnight. Beads were washed once with buffer
1 (20 mM Tris pH 8, 2 mM EDTA, 150 mM NaCl, 1%
Triton X100, 0.1% SDS), once with buffer 2 (10 mM
Tris pH 8, 1 mM EDTA, 500 mM NaCl, 1% Triton
X100, 0.1% SDS), once with buffer 3 (10 mM Tris pH 8,
1 mM EDTA, 250 mM LiCl, 1% NP40, 1% sodium deox-
ycholate monohydrate), and twice with TE buffer. DNA
was eluted by ChIP elution buffer (0.1 M NaHCO3, 1%
SDS, 20 μg/ml proteinase K). The elution was incubated
at 65 °C overnight, and DNA was extracted with a DNA
purification kit (Zymo D4013). The purified DNA was
assayed by quantitative PCR with ABI ViiA 7 and
Power SYBR Green Master Mix (ABI 4368706). For
serial ChIP, the DNA-protein complex of the first IP
was eluted with elution buffer containing no proteinase
K after washing. The elution was diluted 1:9 by dilution
buffer followed by the second IP and washing steps.
Heterozygous genotypes at the candidate loci were
determined using TaqMan SNP genotyping qPCR assays
(Thermo Fisher Scientific C__33991343_10). Assays were
repeated at least three times. Data shown were average
values ± SD of representative experiments.
qPCR primers were designed as follows: SMAD3-1, Fwd:
GGTTGACCCGTTGCATGTTA, Rev: GGAGAGGTG
AAGAGGGCAAA, Amplicon: 129 bp; SMAD3-2, Fwd:
AGAGGGCAGAGAGAGGATAC, Rev: AGTCTTATC
TGCCGGCAAAC, Amplicon: 142 bp; CDKN2BAS, Fwd:
GCATTGAGAAGTCCAGCCAG, Rev: GCAGCAACT
TCGAAGCTTGA, Amplicon: 136 bp.
Immunoprecipitation and western blotting
Nuclear complex Co-IP kit (Active Motif 54001) was
used for co-immunoprecipitation following the manufac-
turer instructions. ChIP samples were eluted with 1×
Laemmli buffer (Bio-Rad 161-0747) containing Halt
protease inhibitor cocktail (Thermo Fisher Scientific
78429) instead of elution buffer for western blotting.
The elution was incubated at 65 °C for 6 h and then
boiled at 95 °C for 2 min. Whole cell lysate samples were
harvested at 4 °C using 1× Laemmli buffer and boiled at
95 °C for 10 min.
The 5–40-μl sample was loaded onto a 4–15% gradient
SDS-PAGE gel (Bio-Rad 4561084DC). Samples were
transferred to polyvinylidene difluoride membrane
(Thermo Fisher Scientific LC2002) for 1 h at 300 mA at
4 °C and blocked with 5% milk in Tris-buffered saline
and 0.1% Tween 20 (TBST, Bio-Rad 1706435) at room
temperature. The membranes were hybridized with the
following primary antibodies: mouse Myc-Tag antibody
(CST 2276S), rabbit SMAD3 antibody (CST 9523S),
rabbit c-JUN antibody (CST 9165S), p300, HDAC1, and
HDAC2 antibodies as described above. Rabbit GAPDH
antibody (Sigma G9545-200UL) was used as the loading
control. Anti-mouse HRP (Jackson ImmunoResearch
115-035-008, 115-035-003, and 115-035-174) or anti-
rabbit HRP (Jackson ImmunoResearch 211-032-171,
111-035-008, and 111-035-003) secondary antibodies
were used at a concentration of 1:10000 and diluted in
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5% milk containing 0.1% Tween 20. Bands were de-
tected using SignalBoost™Immunoreaction Enhancer
Kit (Millipore 407207) per manufacturer’s instructions
on the LI-COR Odyssey imaging system.
ChIPseq analysis
ChIP was performed with approximately 4xE6 HCAMSC
cells using H3K27ac antibody (Abcam ab4729) under JUN
siRNA or TCF21 shRNA knockdown described in the
“Knockdown and overexpression” section. Two biological
replicate DNA were combined for library preparation.
Libraries were prepared with KAPA Hyper Prep kit
(KK8502). ChIPseq libraries were sequenced on HiSeq
X10 for 150 bp paired-end sequencing. Quality control of
ChIPseq data was performed using Fastqc, and then
low-quality bases and adaptor contamination were
trimmed by cutadapt. Filtered reads were mapped to hg19
using BWA mem algorithm. Duplicate reads were marked
by Picard Markduplicate module and removed with
unmapped reads by samtools view -f 2 -F 1804. macs2
callpeak was used for peaks calling with --broad para-
meters and input as control. macs2 bdgdiff was used for
differential peaks calling with default parameters. The
fastq files of TCF21 (SRR1573744&SRR1573745), JUN
(SRR1573749), and HNF1A (SRR5339317) ChIPseq were
extracted from GEO database by fastq-dump. Similar
methods (except --broad parameter in macs2) were used
in quality control, alignment, filtering, and peak calling.
The average fragment size for the JUN ChIPseq was
186 bp, and for TCF21 was 196 bp.
ATACseq analysis
Approximately 5xE4 fresh HCAMSC cells, each with
TCF21 shRNA knockdown or lentivirus overexpression,
and JUN shRNA knockdown (described in the “Knock-
down and overexpression” section) were collected by
centrifugation at 500 g and washed twice with cold PBS.
Nuclei-enriched fractions were extracted with cold
resuspension buffer (0.1% NP-40, 0.1% Tween 20, and
0.01% Digitonin) and washed out with 1ml of cold
resuspension buffer containing 0.1% Tween 20 only.
Nuclei pellets were collected by centrifugation and re-
suspended with transposition reaction buffer containing
Tn5 transposases (Illumina Nextera). Transposition re-
actions were incubated at 37 °C for 30 min, followed by
DNA purification using the DNA Clean-up and Concen-
tration kit (Zymo D4013). Libraries were amplified using
Nextera barcodes and high-fidelity polymerase (NEB
M0541S) and purified using Agencourt Ampure XP
beads (Beckman Coulter A63880) double-size selection
(0.5X:0.9X). For qPCR experiments, the purified DNA
was quantified with ABI ViiA 7 and Power SYBR Green
Master Mix (ABI 4368706) and normalized by genomic
DNA which extracted using Quick-DNA Microprep Kit
(Zymo D3020). Assays were repeated at least three
times. Data shown were average values ± SD of represen-
tative experiments.
Libraries were sequenced on HiSeq X10 for 150-bp
paired-end sequencing. Raw fastq files were evaluated
with fastqc, and then low-quality bases and adaptor
contamination were trimmed by cutadapt. Reads were
mapped to hg19 using bowtie2. Duplicate reads were
marked by Picard Markduplicate module and removed
with unmapped or mitochondrial reads by samtools.
bedtools was used to generate BED file from filtered
reads followed by Tn5 shifting with awk. macs2 callpeak
with --broad and SICER-rb.sh with “W200 G600 E1000”
parameters were used for peak calling. macs2 bdgdiff
and SICER-df-rb.sh with FDR cutoff 0.05 were used
for differential peak comparison in JUN or TCF21
disrupted samples. Bigwig files were generated for
University of California Santa Cruz (UCSC) Genome
Browser visualization.
Peak co-localization and enrichment analysis
The intersectBed was used to find at least 1 bp over-
lapped peaks between H3K27ac, ATAC, TCF21, and
JUN. We combined the open chromatin regions from
ENCODE data as intersection background. P values
were calculated by Fisher’s exact test. For the common
(conserved) open chromatin of ENCODE, we defined
the peaks which have overlaps in more than 50% of the
cell lines (70 out of 126 lines) that are conserved. These
peaks in each line were merged to get the final common
open chromatin regions. For enrichment level analysis,
reads of control/treatment samples which mapped on
peaks were counted by intersectBed and normalized by
per million (RPM). JUN, TCF21 peaks, or open chroma-
tin regions were clustered using the hierarchical algo-
rithm, and reads centering on these peaks (± 2 kb) were
plotted with deeptools.
Cis-regulatory functional enrichment and network
analysis
We utilized the Genomic Regions Enrichment of Annota-
tions Tool (GREAT 3.0) to analyze the detected peaks,
with the parameter “single nearest gene,” which is within
50 kb to nearest genes. Gene ontology from GREAT out-
put was analyzed by DAVID. KEGG pathways, biological
processes, and GAD disease enrichment analysis was
carried out using default settings. The HOMER find-
MotifsGenome.pl script was employed to search for
known TRANSFAC motifs and to generate de novo
motifs. PWMScore was used for position weight matrix
scan. We obtained full-length JUN (MA0488.1) and
TCF21 (MA0832.1) motifs from JASPAR.
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Association of CAD loci and GWAS enrichment analysis
HCAMSC eQTL data came from a genome-wide asso-
ciation of gene expression with imputed common
variation identified in 52 HCASMC lines studied with
whole genome RNA sequencing and 30× whole-genome
sequencing [19]. CARDIoGRAMplusC4D variant data
was from 1000 Genome-based GWAS meta-analyses
[43]. Coronary artery (CA) tissue-specific SNP gene
association data was obtained from GTEx V6p. We inter-
sected open chromatin region which regulated by TCF21
and AP-1 with these three datasets; the significance cutoff
for GTEx is nominal cis-eQTL P < 0.05, FDR < 0.05 for
HCAMSC eQTL, and beta P < 0.05 for CARDIoGRAM-
plusC4D. Overlap of TCF21-AP1 co-regulated open chro-
matin region and GWAS Catalog SNPs was performed
with bed2GwasCatalogBinomialMod1Ggplot script from
gwasanalytics package. The calculation criteria of this
script were described previously [44].
Statistical analysis
All experiments were performed by the investigators
blinded to the treatments/conditions during the data
collection and analysis, using at least two independent
biological replicates and treatments/conditions in tech-
nical triplicate. R or GraphPad Prism was used for statis-
tical analysis. For motifs and gene enrichment analyses,
we used the cumulative binomial distribution test. For
overlapping of genomic regions or gene sets, we used
Fisher’s exact test. For comparisons between two groups
of equal sample size (and assuming equal variance), an
unpaired two-tailed Student’s t test was performed or
in cases of unequal sample sizes or variance, Welch’s
unequal variances t test was performed, as indicated.
P values < 0.05 were considered statistically sig-
nificant. For multiple comparison testing, one-way
analysis of variance (ANOVA) accompanied by Tukey’s
post hoc test were used as appropriate. All error bars
represent standard error of the mean (SE). Number of
stars for the P values in the graphs: ****P < 0.0001,
***P < 0.001, **P < 0.01, *P < 0.05.
Generation and analysis of CRISPR lines
HEK293 cell line was used for genome editing. Cells
were maintained in DMEM containing 10% FBS prior to
and during transfection. Cells were seeded into 6-well
plates at 2 × 105 cells/well and were transfected with
2 μg sgRNA/Cas9-GFP using 7.5 μl Lipofectamine 3000
and 4 μl P3000 reagent per well 24 h after seeding. Two
days after transfection cells were sorted using a Digital
Vantage (BD Biosciences). GFP-positive cells were singly
sorted into two 96-well plates and allowed to grow until
clones reached about 70% confluence, about 2 weeks.
All wells with colonies were marked and then split 1:2
into two fresh 96-well plates. Once a majority of the
wells obtained 80% confluence, one plate of cells was
frozen, and the other was used for genomic DNA extrac-
tion using Qiagen DNeasy Blood and Tissue Kit as per
manufacturer’s instructions. The targeted region was
amplified using 10 μl of gDNA, specific primers
SMAD3_650F, and ChipSeqR and Taq DNA Polymerase
(NEB) as per manufacturer’s instructions. Cycling condi-
tions were as follows: 94 °C for 3 min, 35 cycles of 94 °C
for 1 min, 63 °C for 30 s, 72 °C for 45 s, and one cycle of
72 °C for 5 min. All wells showing a positive band at
about 500 bp were Sanger sequenced with SMAD3_650F
primer, and the sequence was analyzed for indels. The
methods of RNA extraction and expression analysis were
described above.
RNA seq analysis
HCASMC were transfected with TCF21 or scrambled
siRNA using the method described in the “Knockdown
and overexpression” for three biological replicates. The
cells were then collected 48 h after transfection and
processed using RNeasy kit (Qiagen 74106) for RNA iso-
lation. The cells were sent to Novogene for sample QC,
library preparation, and sequencing. All samples passed
QC, and 250–300 bp insert cDNA libraries were pre-
pared for each sample. Subsequently, sequencing was
performed on a Novaseq 6000 platform with paired-end
150 bp reads. The script for RNAseq analysis can be
found in github (https://github.com/milospjanic/rna-
SeqFPro). Briefly, QC of sequencing data was performed
using fastqc. Then, STAR was used to map the reads to
the reference genome (hg19). FeatureCounts from the
Subread package was then used to count the number of
reads mapped, and deseq2 was used to generate the list
of differentially regulated genes.
Results
JUN and TCF21 regulate CAD candidate causal gene
expression in HCASMC
AP-1 and TCF21 are regulatory transcription factors in
human coronary artery smooth muscle cells (HCASMC)
in a number of CAD loci, including SMAD3 and 9p21
[20, 33]. To investigate the specific roles of AP-1 and
TCF21 in regulating CAD gene transcription, we first fo-
cused our investigation on two candidate causal genes,
CDKN2BAS and SMAD3 [33, 38]. siRNA knockdown of
JUN in HCASMC was associated with decreased ex-
pression levels of CDKN2BAS and SMAD3 (Fig. 1a, c,
Additional file 1: Figure S1A). On the other hand,
knockdown of TCF21 produced an opposite effect com-
pared to JUN knockdown, producing increases in
SMAD3 and CDKN2BAS levels (Fig. 1a, c, Additional
file 1: Figure S1A). TCF21 overexpression produced
results opposite to knockdown (Fig. 1a, c, Additional file
1: Figure S1B). Given the known anti-sense effect of
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CDKN2BAS [45], changes in CDKN2BAS expression
were mirrored with opposite effects for the mRNA level of
CDKN2B (Fig. 1a, b). To confirm these gene expression
changes, we investigated the protein level of SMAD3 by
western blotting. The SMAD3 protein level decreased
with JUN knockdown or TCF21 overexpression and
increased with TCF21 knockdown, consistent with mRNA
levels (Fig. 1d, Additional file 1: Figure S1C). These data
suggest that AP-1 serves as a transcriptional activator, and
TCF21 acts as a suppressor of the presumptive CAD
causal genes CDKN2BAS and SMAD3.
JUN increases H3K27ac level and chromatin accessibility
to promote TCF21 binding in SMAD3 and CDKN2BAS CAD
loci
In our previous studies, we identified enhancer regions
associated with SMAD3 and CDKN2BAS genes [33].
The presumptive causal variants located in these regions,
rs17293632 in the SMAD3 enhancer and rs1537373 in
the CDKN2BAS enhancer, are in close proximity to AP1
and TCF21 binding sites [2–4, 33, 35, 46, 47]. These var-
iants are located in HCASMC ATACseq open chromatin
and, by eQTL and allele-specific expression, have been
linked to the expression of SMAD3, CDKN2BAS, or
CDKN2B [33, 34]. Thus, we designed two ChIP-qPCR
primer sets for the SMAD3 enhancer. One set of primers
amplifies the SMAD3-1 region, containing the AP-1
binding motif which is disrupted by rs17293632, and the
second set amplifies the SMAD3-2 region containing the
TCF21 binding motif which is + 505 bp downstream
from AP-1 binding site (Additional file 1: Figure S1D).
However, AP-1 factors can also bind to the SMAD3-2
region to some degree as shown by enrichment for JUN
ChIPseq reads (Additional file 1: Figure S1D), and
although not evident with the genome browser settings
shown, TCF21 can bind to SMAD3-1 with a small but sig-
nificant number of TCF21 ChIPseq reads (Additional file 1:
Figure S1D). Another primer set was designed to amp-
lify the CDKN2BAS-CDKN2B enhancer, containing
both AP-1 and TCF21 binding motifs downstream from
rs1537373 (Additional file 1: Figure S1E). To better
understand the mechanism of how AP-1 affects the
transcription of CAD genes, we evaluated transcription
factor binding and chromatin state in these loci in
HCASMC by ChIP-qPCR. Compared with control
siRNA transfection, JUN knockdown resulted in sig-
nificantly decreased JUN binding in both SMAD3
(SMAD3-1 and SMAD3-2) and CDKN2BAS loci (Fig. 2a).
Since JUN promotes the endogenous expression of TCF21
[20], we overexpressed TCF21 with lentivirus transduction
to maintain the TCF21 expression level in JUN knock-
down and control cells (Fig. 2b, Additional file 1: Figure
S2A, S2B). With sustained TCF21 level in these cells, JUN
knockdown still resulted in reduced TCF21 binding to
these loci (Fig. 2c, Additional file 1: Figure S2A, S2B).
Associated with JUN’s decrease, histone H3K27 acety-
lation was also decreased (Fig. 2d). Lower H3K27ac levels
resulted in decreased chromatin accessibility in these loci
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Fig. 1 JUN and TCF21 regulate expression levels of CAD genes SMAD3 and CDKN2BAS/CDKN2B in HCASMC. a HCASMC were transfected with JUN
(JUN-KD), TCF21 (TCF21-KD), scrambled (Ctrl) siRNA molecules, or transduced with empty pWPI vector (Ctrl) or a human TCF21 cDNA clone
(TCF21-OE) virus. The mRNA expression level of CDKN2BAS was evaluated by qPCR with ACTB normalization. b, c CDKN2B and SMAD3 mRNA
expression levels were quantified under identical conditions in HCASMC (mean ± SD, n = 3). d SMAD3, JUN, and TCF21 protein levels were
evaluated by western blot, with GAPDH as loading control
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(Fig. 2e). These data demonstrate that JUN binding in
these candidate causal CAD loci leads to altered histone
modification, chromatin accessibility, and recruitment of
chromatin remodeling factors, as a potential mechanism
of their effects on gene expression in HCASMC.
JUN recruits EP300 to acetylate H3K27 and open
chromatin in CAD loci
We next investigated how AP-1 complex transcription
factors regulate histone modification and chromatin state.
In vitro purification studies have provided evidence that
the AP-1 complex interacts with histone acetyltransferases
(HATs), suggesting that EP300 (p300) may be involved in
transcriptional regulation in HCASMC [48–50]. To test
this hypothesis, we assessed whether p300 binding in
SMAD3 and CDKN2BAS loci is dependent on JUN
expression level. ChIP-qPCR studies showed p300 binding
requires the presence of JUN as p300 binding is signifi-
cantly decreased in the absence of JUN (Fig. 2f). Consist-
ent with p300’s role as a HAT, JUN overexpression
increased H3K27ac level in the SMAD3 locus, which
could be negated by knocking down p300 (Additional file 1:
Figure S2C, S2D). These studies demonstrated that JUN
regulates H3K27ac of enhancers in a p300-dependent
manner. Interestingly, although JUN effects on TCF21
binding can also be reversed by p300 knockdown, p300
knockdown alone cannot affect the TCF21 binding in
the SMAD3 locus (Additional file 1: Figure S2E).
These findings suggest that it is AP-1, not the histone
modification enzymes, that plays a leading role in
guiding the binding of other TFs, such as TCF21.
To further explore the relationship between AP-1 and
HATs, we employed serial ChIP to study their inter-
actions. With the first immunoprecipitation (IP) using
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Fig. 2 JUN recruits p300, promotes H3K27ac histone modification, and increases chromatin accessibility and TCF21 binding. a–f ChIP-qPCR at
SMAD3-1, SMAD3-2, and CDKN2BAS locus regions with input normalization in HCASMC. a JUN binding was evaluated under conditions of JUN
(JUN-KD) and scrambled (Ctrl) siRNA transfections. b Validation of overexpressed TCF21 mRNA level under conditions of JUN-KD and Ctrl siRNA
transfections by RT-qPCR. c pWI lentivirus expressed TCF21 binding was evaluated under conditions of JUN-KD or Ctrl siRNA transfection. d H3K27ac
level was evaluated under conditions of JUN-KD or Ctrl siRNA transfection. e Chromatin accessibility assessed by ATAC-qPCR was evaluated under
conditions of JUN-KD or Ctrl siRNA transfection. f p300 binding at SMAD3-1/SMAD32 and CDKN2BAS loci was evaluated under conditions of JUN-KD or
Ctrl siRNA transfection. g Serial ChIP-qPCR with JUN first IP followed by p300 second IP. h Serial ChIP-qPCR with p300 first IP followed by JUN second
IP (mean ± SD, n = 3)
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JUN antibody, followed by a second IP using p300 anti-
body with the eluate from the first IP, we observed signifi-
cant enrichment of both JUN and p300 on SMAD3-1 and
CDKN2BAS loci, while the SMAD3-2 locus showed
enrichment for JUN and modest enrichment for p300 that
was not significant (Fig. 2g). With the opposite direction
serial ChIP, we also observed similar enrichment of p300
and JUN at SMAD3-1 and CDKN2BAS loci (Fig. 2h).
Together, these data suggest that p300 is recruited by
AP-1 to the CAD SMAD3 and CDKN2BAS loci, thereby
facilitating JUN-mediated histone acetylation, chromatin
accessibility, and binding of other transcription factors.
TCF21 reduces H3K27ac level and chromatin accessibility
but not JUN binding at CAD loci
In contrast to AP-1, TCF21 appears to function primar-
ily as a transcriptional repressor [22, 23], suggesting that
its effect on transcription in CAD loci might be quite
different from AP-1. This is consistent with other bHLH
factors that oppose AP-1 actions [51]. To better under-
stand how TCF21 modulates gene expression, we inves-
tigated the level of H3K27ac, chromatin accessibility,
and JUN binding in the SMAD3 and CDKN2BAS loci
under TCF21 siRNA knockdown or lentivirus overex-
pression in HCASMC. The ChIP-qPCR data from cells
with TCF21 knockdown show that with decreased
TCF21 binding in these loci (Fig. 3a), the H3K27ac levels
and chromatin accessibility are increased (Fig. 3b, c). De-
creased chromatin accessibility is observed at SMAD3-1
and SMAD3-2 with increased TCF21 expression which
is consistent with the observed effects on H3K27ac
status, although CADKN2BAS shows a slight and un-
expected increase in H3K27ac when TCF21 binding is
elevated by lentivirus (Fig. 3a–c). Interestingly, JUN
binding in these loci is not significantly affected by
reduced or elevated TCF21 binding (Additional file 1:
Figure S3A). Combined with the JUN knockdown data,
these findings suggest that JUN binding is upstream and
likely precedes TCF21 binding, with the AP-1 complex
serving as a pioneer factor that recruits TCF21 itself
after binding DNA and modifying the chromatin envi-
ronment, as has been characterized in the case of the
glucocorticoid receptor [30]. These data are consistent
with our previous observations that JUN activation
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Fig. 3 TCF21 recruits HDACs 1 and 2, promotes deacetylation at H3K27ac, and decreases chromatin accessibility. All panels show ChIP-qPCR at
SMAD3-1, SMAD3-2, and CDKN2BAS locus regions with input normalization in HCASMC. a TCF21 binding, b H3K27ac level, and c chromatin
accessibility (ATAC-PCR) were evaluated under the conditions of TCF21 (TCF21-KD) or scrambled (Ctrl) siRNA transfections or lentivirus
overexpression of TCF21 (TCF21-OE). d HDAC1 and e HDAC2 binding were evaluated by ChIP-qPCR with TCF21-KD. f Serial ChIP-qPCR with TCF21
first IP followed by HDAC1 or HDAC2 second IP. g Serial ChIP-qPCR with HDAC1 first IP followed by TCF21 second IP. h Serial ChIP-qPCR with
HDAC2 first IP followed by TCF21 second IP (mean ± SD, n = 3)
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precedes TCF21 expression [20]. Together, these results
indicate that TCF21 is a suppressor of the two CAD
presumptive causal genes under study here, SMAD3 and
CDKN2BAS, and suggest that the transcriptional inhi-
bition by TCF21 is possibly mediated through H3K27ac,
but that this effect does not alter AP-1 binding.
TCF21 recruits HDAC1 and 2 to deacetylate H3K27 at CAD
loci
It has been previously shown that TCF21 function in the
androgen receptor pathway is histone deacetylase
(HDAC) 1 dependent [52] and that it directly associates
with HDAC2 [53], suggesting a possible mechanism for
how TCF21 suppresses gene transcription in HCASMC.
To answer this question, we evaluated both HDAC1 and
HDAC2 binding in SMAD3 and CDKN2BAS loci in
ChIP-qPCR experiments. These data showed a significant
reduction in both HDAC1 and HDAC2 binding under
TCF21 siRNA knockdown (Fig. 3d, e), along with de-
creased TCF21 binding level (Additional file 1: Figure S3B).
We further investigated the interaction between
TCF21 and HDACs with serial ChIP experiments. With
the first IP using TCF21 antibody, followed by the
second IP using HDAC1 or HDAC2 antibodies from the
elution of the first IP, we observed significant enrich-
ment of both HDAC1 and HDAC2 at SMAD3 and
CDKN2BAS loci in HCASMC (Fig. 3f ). In a second
series of experiments, we performed serial ChIP in the
reverse direction, first IP with HDAC1 or HDAC2 anti-
body and second IP with TCF21 (Fig. 3g, h). These data
suggest that TCF21 recruits HDAC1 and HDAC2 to
SMAD3 and CDKN2BAS genetic loci to deacetylate
H3K27 and thereby suppress transcription.
JUN and TCF21 co-localize at CAD enhancers and directly
interact through protein-protein binding
AP-1 and TCF21 binding sites are juxtaposed in the
SMAD3 and CDKN2BAS loci (Additional file 1: Figure
S1D, S1E), suggesting a possible direct interaction
between these two factors. We employed serial ChIP,
ChIP-western blotting, and co-IP experiments to investi-
gate this hypothesis. First, serial ChIP studies provided
evidence for chromatin-dependent interaction at the
SMAD3 and CDKN2BAS loci. Either with the first IP
using a JUN antibody, followed by a second IP using
TCF21 antibody with the eluate of the first IP (Fig. 4a),
or performing the IPs in the opposite direction (Fig. 4b),
co-enrichment of TCF21 and JUN were detected at the
SMAD3 and CDKN2BAS loci in HCASMC. Second, we
performed ChIP-western blotting experiments with
formaldehyde crosslinked HEK293 cell line transfected
with plasmids encoding myc-tagged TCF21 and native
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Fig. 4 JUN and TCF21 co-occupy chromatin at SMAD3 and CDKN2BAS loci. a Serial ChIP-qPCR with JUN first IP followed by TCF21 second IP. b Serial
ChIP-qPCR with TCF21 first IP followed by JUN second IP (mean ± SD, n = 3). c Interaction between TCF21 and JUN on chromatin was evaluated by
ChIP-western blotting, IP with myc-TCF21 (top) followed by JUN western, or with reverse conditions (bottom). Myc-tagged TCF21 and non-tagged JUN
expression constructs were transfected into HEK293 cells. d Co-immunoprecipitation of TCF21 and JUN with IP of myc-TCF21 followed by JUN western
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JUN. IP was performed with myc-tag or JUN antibodies
in the ChIP buffers followed by reversal of crosslinking
and western blotting (Fig. 4c). These data, from IP per-
formed in both directions, provide additional evidence
for co-localization of AP1 and TCF21 in enhancer regions
of these two CAD loci. Finally, we transfected TCF21 and
JUN plasmids into HEK293 cells and performed direct
co-IP experiments to look for protein-protein interaction
of these factors. The results showed that JUN can be
pulled down with myc-tagged TCF21 IP, and myc-tagged
TCF21 also identified in JUN IP (Fig. 4d). Taken together,
these data provide compelling support for AP-1 and
TCF21 binding together at sites in the genome and
directly interacting via protein-protein binding.
JUN and TCF21 binding is co-localized genome-wide and
these factors regulate H3K27ac levels in the shared loci
We have previously reported ChIPseq data for TCF21
and JUN in HCASMC [23] and documented a signifi-
cant overlap of the binding regions in CAD-associated
loci [33]. To further investigate the co-localization of
JUN and TCF21 binding genome-wide, and the resulting
impact of their binding on local epigenomic features, we
have mapped H3K27ac histone modifications in con-
junction with JUN and TCF21 ChIPseq under knock-
down and control conditions in HCASMC.
First, we compared the binding of native levels of JUN
and TCF21, along with H3K27ac modifications, in the
control ChIPseq datasets. We found co-localization of
TCF21 and H3K27ac enrichment centered on total
85,695 JUN peaks, compared with the negative control
TF HNF1A. Visualization of this co-localization with a
density plot for normalized ChIPseq peaks showed
H3K27ac modification overlapping and flanking the JUN
peaks, along with TCF21 overlap as previously described
(Fig. 5a) [33]. Focusing on a total 42,490 TCF21 peaks
revealed co-localization of JUN binding and H3K27ac
marked regions. A density plot showed more prominent
overlap with JUN binding and H3K27ac mapping with a
similar pattern of co-localization (Fig. 5b). We also plot-
ted position weight matrix (PWM) scans for predicted
binding at JUN and TCF21 peaks, which showed similar
co-localization of the TFs (Additional file 1: Figure S4A,
S4B). To quantify the number of overlapping JUN and
TCF21 peaks, we intersected these two groups of ChIP-
seq peaks, identifying 12,033 TCF21 peaks that directly
overlap with JUN peaks (P < 1.41e−91, Fig. 5c). The
overlapped TCF21 peak number increased rapidly with
the distance from JUN, and more than 70% of TCF21
peaks (30,120 out of 42,490) are found less than 10 kb
from JUN binding sites (Fig. 5c), suggesting relative
proximity of their binding genome-wide and possible
regulatory interactions.
Co-localization of binding was verified by investigating
the binding site distance from the control factor
HNF1A, a TF that is functional primarily in the liver,
and has different binding features from TCF21 and
AP-1. We intersected DNaseI open chromatin data for
HepG2 liver cells from ENCODE and our ATACseq data
for HCASMC to get the common open chromatin
regions in these two cell types, and analyzed the closest
distances of binding sites for these various factors. The
histogram of distance shows no significant difference
between the spacing of TCF21 from JUN, JUN from
TCF21, or TCF21 from HNF1A in the common open
chromatin regions (Additional file 1: Figure S4D). How-
ever, if we exclude the common open regions of ENCODE
from HCASMC open regions to obtain HCASMC-specific
open chromatin regions, the median distance between
binding sites of TCF21 and JUN is 12,781 bp, while that of
TCF21 and HNF1A is 78,559 bp (Additional file 1: Figure
S4E), suggesting that the co-localization of TCF21 and
JUN is smooth muscle cell type-specific.
Since we have shown that AP-1 and TCF21 can both
modulate H3K27ac histone modification in CAD loci in
HCASMC, we were interested in mapping and com-
paring loci across the genome where these TFs regulate
H3K27ac status in HCASMC. Thus, we performed
H3K27ac ChIPseq under TCF21 shRNA or JUN siRNA
knockdown, obtaining 24,065 and 24,883 total peaks
under these conditions, respectively. Heatmap distribu-
tions of JUN peaks showed genome-wide enrichment of
TCF21 binding, with enrichment of H3K27ac showing a
flanking pattern (Fig. 5d) as in the density plot, and
diminished signal in the JUN knockdown condition.
Similar heatmaps of TCF21 binding showed enrichment
for JUN co-localization, with more widely distributed
H3K27ac enrichment that is more pronounced with
TCF21 knockdown (Fig. 5e). To quantify the change in
H3K27ac status genome-wide, we evaluated the average
enrichment levels on H3K27ac peaks found in the
sequencing data. Compared with scrambled control,
H3K27ac level in JUN siRNA knockdown showed a
change in peak length distribution with shorter length
peaks with JUN knockdown and longer peaks with
TCF21 knockdown (Fig. 5f, g) (Wilcoxon tests, both
P < 2.2e−16).). In addition, JUN siRNA knockdown
showed a modest but significant reduction in H3K27ac
peak height for all peaks (Fig. 5h), while the level in
TCF21 shRNA knockdown showed a significant increase
(Fig. 5I).
Further, we identified loci where H3K27ac is regulated
by both JUN and TCF21 in HCASMC. With JUN knock-
down, we obtained 10,882 decreased and only 391
increased H3K27ac peaks compared with control. On
the other hand, 42 decreased and 14,234 increased
H3K27ac peaks were found in TCF21 knockdown.
Zhao et al. Genome Medicine           (2019) 11:23 Page 10 of 18
With a more stringent q value cutoff (q < 1e−10 for
TCF21 and q < 1e−5 for JUN), chosen to give equiva-
lent numbers of peaks, we found 7017 peaks with
H3K27ac increased with JUN knockdown and 6026
peaks with H3K27ac decreased with TCF21 knock-
down. Out of these, 3093 peaks were directly overlapping
(Additional file 1: Figure S4F). We also intersected those
3093 overlapping H3K27ac peaks with TCF21 and JUN
ChIPseq peaks, showing that 749 peaks overlap with
TCF21, 699 with JUN, and 224 with both (Additional file 1:
Figure S4G). Therefore, 1124 H3K27ac peaks overlap with
at least one of the two transcription factor ChIPseq sites,
suggesting that more than one third of these sites are
directly regulated by TCF21 and JUN, while two thirds are
indirectly regulated by TF downstream of TCF21 and
JUN. These data indicate that H3K27ac level is regulated
at the genome-wide level by AP-1 and TCF21, thus sup-
porting our ChIP-qPCR data and suggesting a genome-
wide epigenomic interaction of these factors. Overall,
changes in H3K27ac level with JUN knockdown were not
as pronounced as those seen for TCF21 knockdown,
possibly due to the fact that there are a number of bZip
factors that can bind and regulate H3K27ac at AP-1 sites
in addition to JUN, leading to a smaller effect size.
Finally, we employed Genomic Regions Enrichment of
Annotations Tool (GREAT) to assign the common 3093
H3K27ac regions to genes, and this collection of 2580
target genes were used in gene ontology analysis with
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DAVID. Significant terms identified by the Biological
Process analysis included VEGF, TGFβ and EGF signal-
ing pathways, cell adhesion, migration, and proliferation,
which are highly relevant to smooth muscle cellular
functions (Additional file 1: Figure S4H, Additional file 2:
Table S1). Significant KEGG terms included VEGF,
TGFβ and Hippo pathways, focal adhesion, and cell
cycle (Additional file 1: Figure S4I, Additional file 2:
Table S1). These data suggest that AP-1- and TCF21-
regulated H3K27ac loci are highly associated with
basic HCASMC functions that are relevant to CAD
pathophysiology.
JUN and TCF21 regulate chromatin accessibility in
HCASMC
Open chromatin regions in HCASMC are enriched for
CAD-associated loci and GWAS variants [19, 33]. To in-
vestigate the epigenetic implications of these observa-
tions, we employed ATACseq to generate epigenomic
profiles in HCASMC with JUN knockdown, TCF21
knockdown, and TCF21 overexpression. With TCF21
knockdown, we obtained 54,298 increased open chroma-
tin regions and 2218 decreased regions; while 9932 de-
creased regions were found with TCF21 overexpression,
all with q < 0.01. Since TCF21 is mainly identified as a
transcriptional suppressor [22, 44], we intersected the
54,298 increased regions with knockdown and the 9932
decreased regions with overexpression, identifying 5063
overlapped high confidence TCF21 targets. Similarly, we
intersected 110,373 and 109,143 decreased regions iden-
tified with JUN knockdown by two different shRNAs,
shJUN-1 and -2, thus identifying 37,352 JUN high confi-
dence ATACseq targets with q < 1e−10 and fold change
< 0.5. There were 2587 overlaps within the TCF21 and
JUN target regions, which we identified as loci regulated
by the two TFs with high confidence (P < 6.2e−83,
Fig. 6a). We also integrated these loci with ChIPseq pro-
files for JUN and TCF21 binding as well as those for
H3K27ac modifications. A large portion of the 2587 JUN
and TCF21 ATACseq targets overlap with TCF21 and
JUN peaks; 1043 with TCF21, 2111 with JUN, and 885
with both (Fig. 6b). The H3K27ac peaks were also highly
enriched in the open chromatin regions of JUN or
TCF21 knockdown, with ~ 90% overlap with ATAC
peaks (Additional file 1: Figure S5A, S5B). Further, we
centered the 2587 loci for heatmap clustering, showing
the co-localization of these open chromatin regions with
JUN and TCF21 binding, but not with the negative con-
trol HNF1A (Fig. 6c). The enrichment levels of ATAC-
seq on these loci are reduced in JUN knockdown while
they are upregulated in TCF21 knockdown and down-
regulated in TCF21 overexpression (Fig. 6c), which is
consistent with the regulated peak numbers above. We
also discovered several AP-1 and TCF21/TCF12 binding
motifs using the HOMER “known” motif analysis on
these 2587 loci with low P values (Additional file 1:
Figure S5C). These analyses provide a map of genomic
regions targeted by AP-1 and TCF21 in HCAMSC.
To investigate the genes in the open chromatin regions
where JUN and TCF21 are co-localized, we assigned those
loci to genes using GREAT. At the identified 936 genes,
chromatin accessibility is downregulated by TCF21 and
upregulated by JUN, especially around the TSS (Fig. 6d).
At the SMAD3 and CDKN2BAS enhancers studied
above, we observed pronounced chromatin accessibility
differences with JUN or TCF21 disruptions (Fig. 6e). In
addition, smooth muscle cell marker genes such as
ACTA2 and MYH11 were regulated with similar direc-
tionality (Additional file 1: Figure S5D). At the genome
level, GO analysis identified a large number of the 936
genes to be significantly enriched in smooth muscle cell
functions and CAD-associated terms, including vascu-
logenesis, angiogenesis, cell adhesion, and proliferation in
biological processes; myocardial infarction, cardiovascular
diseases, and coronary artery calcification in GAD enrich-
ment; ECM and cell adhesion in KEGG pathways (Fig. 6f,
g, Additional file 1: Figure S5E, Additional file 3: Table S2,
Additional file 4: Table S3). The change in chromatin
accessibility results in differential expression levels of
those genes, ~ 2/3 of which are upregulated in mRNA
level with TCF21 siRNA knockdown (Additional file 1:
Figure S5F, Additional file 4: Table S3). In summary, these
data reveal that AP-1 and TCF21 regulate chromatin
modification and accessibility genome-wide in loci that
regulate fundamental SMC processes; some of which are
important mediators of CAD risk.
CAD-associated variants are enriched in open chromatin
regions regulated by JUN and TCF21
Given that the variation in chromatin accessibility and
TF binding is a dominant mechanism of variation in
gene expression, we were interested to identify and
experimentally validate variants located in the 2587
regions of the genome that are regulated by AP-1 and
TCF21 in HCASMC (Fig. 6a). First, we intersected those
open chromatin regions with the GTEx Coronary Artery
(CA) eQTL public variant database [54], as well as
eQTLs we have mapped in HCASMC (q < 0.05) [19],
and CARDIoGRAMplusC4D CAD [43]-associated SNPs
(P < 0.05). There were 491 GTEx CA and 643 HCASMC
eQTLs, and 857 CARDIoGRAMplusC4D SNPs located
in these loci (Additional file 1: Figure S6A) [2, 4, 19, 55].
In particular, 643 HCASMC eQTLs were associated with
193 genes, which were enriched in CAD-associated
terms in GO analysis [19]. Identified terms are quite
similar to those found in AP-1- and TCF21-targeted loci
(Additional file 1: Figure S6B, C, D, Additional file 5:
Table S4). The expression level of these genes was also
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investigated in a previous TCF21 knockdown RNAseq
study [22], showing that > 70% differentially expressed
genes are elevated at the transcriptional level (Add-
itional file 1: Figure S6E). With a second approach,
employing the GWAS catalog with CARADIoGRAM
+C4D data added, we intersected all GWAS variants
within AP-1 plus TCF21-targeted regions of open chro-
matin; the results show that significant (low P values)
and highly enriched (high fold change) GWAS CAD
SNPs were found in those regions (Additional file 1:
Figure S6F). Further, we overlapped the JUN and TCF21
intersected peaks, (Additional file 1: Figure S6G), total
TCF21 peaks (Additional file 1: Figure S6H), and total
JUN peaks (Additional file 1: Figure S6I) with GWAS
catalog SNPs. CAD-associated terms were highly enriched
in overlapped regions of the two ChIPseq datasets com-
pared to the individual datasets. Terms “CARDIoGRAM
+C4D,” “Coronary Artery Calcification,” and “Coronary
Artery” showed a 3–6-fold enrichment in the overlapping
data analysis while JUN, and TCF21 alone had only
1–3-fold enrichment.
Allele-specific binding of JUN and TCF21 leads to a
transcriptional imbalance of presumptive CAD causal
genes
With these data regarding the role of AP-1 and TCF21
in genome-wide regulation of epigenetic features in
CAD loci, we wanted to investigate the effect that such
features have on allele-specific TF binding and CAD
gene expression. In these experiments, we employed
HCASMC from individuals heterozygous for candidate
CAD regulatory SNP rs17293632 at SMAD3 that localize
to a validated canonical AP-1 site in this gene [33]. The
native C allele that is consistent with AP-1 factor binding
was found to be associated with allelic expression im-
balance of SMAD3 as detected by qRT-PCR, along with
evidence of allelic differences in chromatin accessibility as
reflected by ATACseq read counts, allele-specific binding
of JUN, TCF21, and H3K27ac as identified with hap-
loChIP studies (Fig. 7a).
To more formally address this question, we conducted
follow-up studies in cells with CRISPR/Cas9 genome
editing of the SNP rs17293632 in HEK293 cells. A series
of edited lines were identified by genomic sequencing. A
motif deleted (DEL) line and a single base-pair alteration
line (ALT) which edited the C to T allele showed
decreased SMAD3 expression compared to the native
allele (Fig. 7b). These lines were used in ChIP-qPCR
experiments which showed that motif deletion causes a
significant reduction of JUN binding at rs17293632, as
did the single nucleotide alteration (Fig. 7c). The
decreased JUN binding can be observed at the edited
rs17293632 loci but not with the native rs1537373
CDKN2BAS variant. The JUN-dominant negative factor
A-FOS can reduce the binding on both loci, showing
that the reduction of JUN binding is caused by site-spe-
cific genome editing (Fig. 7c). We also investigated
TCF21 binding and the chromatin state at these loci.
Since no endogenous TCF21 expression was detected in
HEK293 cells, we overexpressed TCF21 in these lines using
lentivirus transduction. As expected, decreased JUN bind-
ing level resulted in reduced TCF21 binding, H3K27ac
level, and chromatin accessibility at rs17293632 but not at
rs1537373 (Fig. 7d–f). These data demonstrate that CAD
variants can lead to allele-specific TF binding and im-
balanced expression level of regulated genes.
Discussion
In conjunction with previously published data, the data
presented here indicate that there are multiple mecha-
nisms by which AP-1 factors may regulate transcription
in CAD-associated loci and thus a disease risk. First,
there are now several examples of AP-1 binding sites
which are altered by causal variation, leading to differ-
ences in gene expression. An AP-1 cognate binding site in
an intron of the SMAD3 gene has been shown to regulate
expression of this gene and implicated as causal for both
CAD and autoimmune diseases [20, 32, 34, 35, 56]. Also,
causal variation at two CAD-associated alleles of TCF21
disrupts canonical AP-1 binding sites, which binds AP-1
factors and promotes expression of TCF21 [20]. A second
mechanism, delineated by work presented here, provides
compelling evidence that AP-1 may regulate expression of
nearby TFs or chromatin regulatory features that are
causal in disease loci by altering nearby epigenetic features
and chromatin accessibility, i.e., through pioneer epige-
netic functions (Fig. 8). This mechanism can also be
extended to include the situation presented here whereby
AP-1 regulates the binding and function of another func-
tional TF such as TCF21, that in turn regulates the causal
transcriptional mechanism. Finally, AP-1 factors are well
known to interact with bHLH factors such as MYOD [57],
and this fact in conjunction with evidence presented
here for TCF21-AP-1 interaction suggests that AP-1
may modulate binding of other TFs through direct
protein-protein interaction.
These data add to our understanding of how TCF21
affects CAD gene expression and function. TCF21 has a
developmental role in coronary smooth muscle, spe-
cifically suppressing the expression of SMC lineage
markers through transcriptional regulation/suppression
(e.g., ACTA2) and possibly affecting the myocardin-SRF
complex which serves as a master regulator in this cell
type. Loss of TCF21 leads to increased SMC differenti-
ation of CASMC. Reactivation of TCF21 may have a simi-
lar role in SMC in disease, promoting dedifferentiation
and migration, which is protective in this setting, based on
directionality from human genetics studies [21, 22]. In
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addition to its capacity to regulate the transcriptional
effect of the causal variant in the CAD locus, these data
show that TCF21 has another mechanism of effect, which
works through local epigenetic modification to regulate
access of TFs and chromatin regulators to modulate gene
expression. Further, these studies suggest that TCF21 can
serve as a lineage partner for AP-1, similar to what has
been shown for AP-1 interactions with PU.1 in macrophages,
and ETS and GATA factors in endothelial cells where AP-1
promotes cell-restricted enhancer function [28, 58].
One important question that arises from these studies
is the nature of the TCF21-AP-1 interaction in terms of
CAD gene expression and disease risk. AP-1 is activated
and binds to the SMAD3 and CDKN2BAS CAD loci,
recruiting HAT activity and thus promoting an open
chromatin configuration (Fig. 8). This promotes TCF21
binding, which in turn recruits HDACs, thus setting up
a competition for the status of local chromatin confi-
guration. The best explanation for these findings is that
they represent a counter-regulatory pathway, with in-
dependent upstream epigenetic pathways regulating one
or the other of these factors, and overall disease versus
risk being determined by the cellular milieu in the vas-
cular wall. It is important to note that the balance of regu-
lation of promotion versus inhibition of transcription is
more complex than just TCF21-AP-1 interactions, as
these factors also likely regulate binding of CTCF, CEBP,
and other TFs that bind in this region through their
epigenetic effects. Importantly, for the SMAD3 and
CDKN2BAS presumptive causal genes, TCF21 inhibits
disease-promoting effects of AP-1 on the risk alleles at
these two loci [19, 33]. The same type of relationship has
been characterized at CAD loci where TCF21 interacts
with SMAD3, with the binding of both of these factors
co-localizing genome-wide in a number of CAD loci [37].
That interaction is also primarily competitive, with TCF21
blocking SMAD3 binding through epigenetic modulation.
The effects of SMAD3 expression are opposite to TCF21
and promote disease risk, whereas AP-1 can be both
protective through the promotion of TCF21 expres-
sion, and risk promoting through increasing SMAD3
expression [37].
While these studies highlight the interaction of AP-1
factors with TCF21 in loci that are linked to CAD, they
likely represent a mechanism that is applicable to other
human diseases. For instance, the mapped loci showing
co-localization of AP-1 and TCF21 are enriched for genes
that contribute to VEGF, TGFβ, EGF, Hippo, focal adhe-
sion, and cell cycle biological processes (Additional file 1:
Figure S4H). These terms are well known to associate with
various forms of cancer, and the data presented here are
consistent with both the involvement of AP-1 and TCF21
interactions in the biology of the tumor cell, since TCF21
is a well-known tumor suppressor [59], as well as the
angiogenic processes that support tumor growth and
expansion [60, 61].
Conclusions
These data characterizing the TCF21-AP-1 counter-
regulatory pathway in CAD loci suggests that the epigenetic
Fig. 8 Mechanism of TCF21 and AP-1 epigenetic interactions in the context of CAD-associated genetic loci. TCF21 is a bHLH transcription factor
associated with CAD as depicted here due to allelic variation in causal variants (Y), and its transcriptional regulatory function accounts for the
attributable genetic risk at the 6q23.2 locus (brown oval). TCF21 binding is enriched in other CAD loci, where it interacts with AP-1 factors (JUN)
that co-localize at these sites (gray oval). JUN promotes recruitment of HAT p300 to promote H3K27ac histone acetylation and open chromatin to
recruit TFs, including TCF21, which in turn recruits HDACs 1 and 2 that function to oppose AP-1 effects. These epigenetic effects contribute in cis
to the regulation of expression of the causal gene through alteration in the binding of the causal TF through CAD-associated variant Z (green
circle) or other mechanisms of disease at this locus. Such interactions likely contribute to attributable genetic risk at both the TCF21 and
downstream loci
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landscape in disease loci is more complex than previously
thought and that part of the attributable risk for
CAD-associated transcription factors such as TCF21
may be due in part to their functions in trans, me-
diated by epigenetic effects at other CAD loci across
the genome. The risk that resides in each disease locus
would thus be a combination of the local mechanism
involving the causal allele and gene, as well as that
due to modulation of the epigenome by TFs such as
TCF21 (Fig. 8).
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